Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03752177 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3415244 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03752177 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 12 participants.
The verdict
NCT03752177, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.
Interventions
- DRUG LY3415244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-11-22 |
| Est. Completion | 2019-10-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03752177
The ClinicalTrials.gov registry entry for NCT03752177 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3415244 is the first listed.
NCT03752177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03752177 about?
NCT03752177 is a clinical study titled "A Study of LY3415244 in Participants With Advanced Solid Tumors". The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.
What is the current status of trial NCT03752177?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-11-22. Estimated completion is 2019-10-09.
What interventions are being tested in trial NCT03752177?
The interventions under investigation include: LY3415244 (DRUG).
Who is sponsoring clinical trial NCT03752177?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.